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Abstract
Background—Ocular syphilis is an inflammatory eye disease due to Treponema pallidum 
infection. In the United States, syphilis rates have increased since 2000; clusters of ocular syphilis 
were reported in 2015. We investigated ocular syphilis in North Carolina to describe the 
epidemiology and clinical course of disease.
Methods—We reviewed syphilis cases reported to North Carolina during 2014–2015 and 
abstracted information from health department interviews for cases with ocular symptoms and no 
other defined etiology. To assess duration and severity of ocular symptoms, we also reviewed 
medical records and conducted structured interviews. We compared the prevalence of ocular 
manifestations among reported syphilis cases by demographic and clinical characteristics.
Results—Among 4232 syphilis patients, 63 (1.5%) had ocular syphilis: 21 in 2014 and 42 in 
2015, a 100% increase. Total syphilis cases increased 35% through 2015. No patient with ocular 
syphilis named another ocular syphilis patient as a sex partner. Patients presented in all syphilis 
stages; 24 (38%) were diagnosed in primary or secondary syphilis. Ocular manifestations were 
more prevalent among syphilis patients who were male, aged ≥40 years, white, and infected with 
human immunodeficiency virus. No risk behaviors were associated with ocular syphilis. Among 
39 interviewed patients, 34 (87%) reported reduced vision during infection; 12 (31%) reported 
residual visual symptoms posttreatment.
Conclusions—In North Carolina, ocular syphilis increased from 2014 to 2015 and may be due 
to increased recognition of ocular manifestations, or a true increase in ocular syphilis. Many ocular 
syphilis patients experienced vision loss; however, most improved posttreatment.
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Syphilis is a genital ulcerative disease caused by the spirochete Treponema pallidum that can 
cause multisystem disease with a variety of clinical manifestations. In the United States, 
rates of syphilis have been increasing since 2001, with the number of total syphilis cases 
reported to the Centers for Disease Control and Prevention (CDC) increasing 17.7% in 2015 
compared with 2014. These increases are largely attributable to an increase in syphilis 
among men who have sex with men (MSM) [1].
Previous studies describing clusters of ocular syphilis have identified involvement with most 
eye structures, in any stage of syphilis, and with acute or chronic manifestations [2–5]. 
Uveitis is the most common ophthalmologic diagnosis observed; optic neuritis, retinitis, and 
retinal detachment also have been diagnosed [4–7].
While syphilis is a nationally notifiable disease, CDC has not systematically collected 
surveillance data on ocular manifestations; therefore, national rates of ocular syphilis over 
time are unknown. Studies have found frequencies of ocular manifestations ranging from 0% 
to 7.9% of patients with secondary syphilis [8, 9], and up to 51% of patients with 
neurosyphilis [10]. A review of surveillance data during 2012–2013 from King County, 
Washington, revealed that 4.8% of patients with syphilis reported visual symptoms and 2.7% 
had objective findings consistent with ocular syphilis [11]. In England, national surveillance 
data showed that 0.6% of patients with early syphilis diagnoses had ocular manifestations 
[6].
In early 2015, CDC was notified about 2 clusters of ocular syphilis reported from Seattle and 
San Francisco [12] and issued a clinical advisory [13] in April 2015 to increase clinician 
awareness and public health reporting. Since then, many states have received reports 
regarding severe visual symptoms among patients diagnosed with syphilis. A review of 
ocular syphilis in 8 US jurisdictions found ocular manifestations from syphilis in 0.61% of 
total syphilis cases, increasing from 0.53% in 2014 to 0.65% in 2015 [14]. Molecular typing 
of Treponema pallidum strains was performed on samples from US patients with ocular 
syphilis; 5 strains were identified in 14 patients, suggesting there is not a single type 
responsible for this increase [15].
The North Carolina Division of Public Health (NC DPH) performed a preliminary review of 
syphilis surveillance data for ocular manifestations and found an increase from 2014 to 
2015, potentially out of proportion to the rise in all reported cases of syphilis. Several 
accounts of severe outcomes related to ocular syphilis, including blindness, were reported as 
well. In response, the NC DPH invited CDC to assist with systematically reviewing North 
Carolina's ocular syphilis cases during 2014–2015. The aims of the investigation were to: 
estimate the prevalence of ocular syphilis; describe clinical symptoms, diagnosis, and 
treatment; and to identify possible risk factors for ocular manifestations.
Methods
North Carolina providers are required by law to report all newly diagnosed cases of syphilis 
to local health departments. Once reported, health department staff verify treatment, collect 
syphilis-related signs and symptoms from the reporting provider, and attempt to interview 
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each case to identify risk behaviors and sex partners at risk of transmitting syphilis. Health 
department staff enter all case report data into the North Carolina Electronic Disease 
Surveillance System (NC EDSS).
We reviewed cases in all stages of syphilis entered into NC EDSS; a patient meeting the 
syphilis surveillance case definition [16] with ocular symptoms not explained by another 
etiology was considered a case of ocular syphilis.
We identified 83 potential cases of ocular syphilis from 1 January 2014 to 31 December 
2015 using 2 ascertainment methods (Figure 1). First, we identified cases where a checkbox 
indicated “eye/conjunctiva” was a site of infection. Second, we searched free-text fields 
from syphilis case investigation notes, using key words (eg, eye, vision, sight, or blind). The 
“eye/conjunctiva” checkbox was a standard component of the syphilis case report form 
before this investigation, but disease investigation specialists (DIS) were encouraged to ask 
all investigated syphilis cases about eye symptoms and utilize the checkbox in early 2015.
For all identified ocular syphilis cases, we reviewed data in NC EDSS and abstracted 
demographic information, syphilis testing, symptoms and treatment, sexual behavior, partner 
information, and other risk factor information. We also requested medical records from 
reporting providers and reviewed records for clinical visits associated with the ocular 
syphilis diagnosis to document additional symptoms, risk, treatment, and comorbidities. We 
characterized ocular syphilis cases and compared symptoms by human immunodeficiency 
virus (HIV) status. We estimated ocular syphilis prevalence among all syphilis cases 
reported to NC EDSS by demographic, behavioral, and clinical characteristics.
Follow-up Interviews
NC DIS from the Ocular Syphilis DIS Workgroup attempted to contact all ocular syphilis 
patients for a follow-up interview to assess symptoms and resolution, medical care, 
insurance status, and visual function. We assessed visual function using questions from the 
Visual Function Questionnaire (VFQ-25) [17]. We asked patients to rate overall visual 
function from blind to excellent. We also asked patients to rate the difficulty level of 
multiple vision-related tasks using a numeric scale from 1 (unable to perform activity 
because of eyesight) to 5 (no difficulty). Visual function questions were asked at 3 time 
points: before having eye/vision problems related to syphilis, when symptoms related to 
syphilis were at their worst, and at the time of the interview. At each time point, we 
calculated mean visual function score by activity.
We considered a severe eye diagnosis to be retinitis, optic neuritis, or retinal detachment. We 
defined recommended treatment as 10–14 days of intravenous (IV) aqueous penicillin G 
[18]. We defined vision loss as a follow-up questionnaire response indicating vision loss in 
either eye. We defined residual symptoms as reported visual function worse than baseline.
Statistical Analysis
We compared the distribution of demographic factors, syphilis characteristics, behavioral 
risk factors, clinical characteristics, and visual function using χ2 tests; Fisher exact P values 
were reported where cell sizes were <5. Associations between ocular syphilis and median 
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rapid plasma reagin (RPR) titers were assessed using the Wilcoxon rank-sum test. We 
compared prevalence estimates using log binomial models to estimate prevalence ratios 
(PRs) and 95% confidence intervals (CIs). We considered an α value ≤.05 statistically 
significant. Data were analyzed using SAS version 9.3 software (Cary, North Carolina).
Results
In North Carolina, syphilis cases diagnosed in any stage increased 35%, from 1799 cases in 
2014 to 2433 cases in 2015. A total of 63 ocular syphilis cases were identified: 21 in 2014 
and 42 in 2015, a 100% increase. Ocular syphilis cases represented 1.5% of all reported 
syphilis cases in North Carolina during 2014–2015, and were distributed among 33 of 100 
counties. No patients with ocular syphilis named another ocular syphilis patient as a sexual 
partner, and no other epidemiologic links were found between cases, such as travel or an 
institutionalized setting.
Most ocular syphilis patients were male (n = 59 [94%]); of those, 42 (71%) stated they had 
male sex partners (Table 1). The mean age was 45 years (range, 21–79 years). Primary or 
secondary syphilis was diagnosed in 24 (38%). Median RPR was 1:128 and varied slightly 
by stage of disease (primary or secondary syphilis = 1:256; all latent syphilis [early, late, and 
latent of unknown duration] = 1:128). A variety of syphilis symptoms were reported; a 
recent skin rash was most common. However, 25 (40%) patients reported no recent syphilis 
symptoms other than ocular symptoms. Forty-two patients (67%) received the recommended 
treatment for ocular syphilis, and 13 (21%) patients received intramuscular (IM) benzathine 
penicillin only. Among 38 ocular syphilis patients who had a lumbar puncture with 
cerebrospinal fluid (CSF) analysis, 24 (63%) had a reactive CSF Venereal Disease Research 
Laboratory test (VDRL).
Overall, 49 patients (78%) had a documented eye examination consistent with ocular 
syphilis. Uveitis (anterior uveitis, posterior uveitis, or panuveitis) was the most common 
diagnosis documented in the eye examination. Fifteen patients received a severe eye 
diagnosis; 1 patient was diagnosed with retinitis and retinal detachment.
A total of 35 (56%) patients were HIV infected; 11 of whom (31%) were diagnosed with 
HIV at the same time as ocular syphilis. Similar proportions of HIV-infected and 
HIVuninfected ocular syphilis patients had a severe eye diagnosis, CSF analysis performed, 
or positive CSF VDRL. However, a larger proportion of HIV-infected patients with a CD4 
count <350 cells/μL reported only ocular symptoms of syphilis (55.6%), compared with 
HIV-infected patients with a CD4 count ≥350 cells/μL (10%).
Factors Associated With Ocular Syphilis
Ocular syphilis was more prevalent in syphilis patients who were male (PR, 2.82; 95% CI, 
1.03–7.73), white (PR, 2.63; 95% CI, 1.60–4.32), >40 years of age (PR, 3.27; 95% CI, 1.98–
5.39), and HIV infected (PR, 1.78; 95% CI, 1.09–2.92) (Table 2). Patients diagnosed with 
ocular syphilis had a higher median RPR titer than patients with nonocular syphilis (1:128 
vs 1:32, P < .0001). No behaviors were associated with ocular syphilis (eg, drug use, sex 
parties, meeting partners via internet sites or apps).
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Follow-up Interviews
Among the 63 ocular syphilis patients identified, 39 (62%) were interviewed (Figure 1). 
Median time from ocular syphilis diagnosis to interview was 10 months (range, 3–25 
months). Among 39 patients who completed interviews, 27 (69%) had health insurance at 
the time of ocular syphilis diagnosis: 18 (67%) patients had private insurance, and 9 (33%) 
had government insurance. A total of 26 (67%) patients received care from an eye doctor, 7 
of whom also received care elsewhere (ie, emergency room, primary care physician, sexually 
transmitted disease, HIV, or infectious disease clinic). An additional 12 (32%) patients did 
not receive care from an eye doctor, but did receive care at another location. One patient had 
no documented treatment, 8 (21%) received IM penicillin only, 28 (72%) received 
recommended IV penicillin, and 2 (5%) received other treatment (doxycycline or 
ceftriaxone).
The median number of days from onset of symptoms to initial healthcare visit was 14 days; 
median number of days from initial visit to initiation of syphilis treatment was 10 days. We 
did not detect any associations between age, race, HIV status, insurance, presenting 
symptoms, and location of care with number of days between symptom onset and initial 
healthcare visit. However, patients presenting only with ocular symptoms were more likely 
to be seen by an eye doctor (86.7% vs 54.2%; P = .04) and to have >10 days between 
seeking care and treatment initiation (55.6% vs 23.8%; P = .04), compared to those 
presenting with additional syphilis symptoms. The median time from care to initiation of 
treatment for patients who saw an eye doctor (including patients who also sought care at 
another location) was 13 days (range, 1–210 days); median time for patients who did not see 
an eye doctor was 7 days (range, 0–210 days).
Thirty-three (85%) patients reported good or excellent eyesight (with glasses or contact 
lenses, if needed) prior to ocular syphilis. When ocular symptoms were at their worst, only 5 
(13%) patients reported good or excellent eyesight, and 4 (10%) reported blindness. At the 
time of the interview, 31 (80%) reported good or excellent eyesight; 1 (3%) patient reported 
blindness. A similar pattern was reported when patients were asked about visual impairment 
during daily activities such as driving, reading, and working, at the same 3 time points 
(Figure 2).
Twelve patients reported worse visual function at the time of the interview, compared with 
before ocular syphilis diagnosis. Patients with residual deficits had been diagnosed with 
panuveitis, anterior uveitis, chorioretinitis, and retinal detachment; none diagnosed with 
scleritis, keratitis, optic neuritis, or posterior uveitis alone had residual deficits. Age, race, 
HIV status, timing of care and treatment, and location of treatment were not associated with 
residual visual function deficits. However, a lack of more common syphilis-related 
symptoms was associated with residual deficits; of 15 patients presenting only with ocular 
symptoms, 6 (40%) developed residual deficits, compared to 6 of 24 (25%) who presented 
with additional syphilis-related symptoms. Five (42%) patients with residual deficits had 
health insurance at the time of ocular syphilis diagnosis; in comparison, 22 of 27 (81%) 
patients without residual disease were insured at the time of diagnosis (P = .01).
Oliver et al. Page 5
Clin Infect Dis. Author manuscript; available in PMC 2018 October 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
In this in-depth analysis of ocular syphilis, we found an increase in ocular syphilis cases in 
North Carolina from 2014 to 2015, in the setting of increased awareness of ocular 
manifestations of syphilis. Ocular syphilis was diagnosed in all stages of syphilis and in both 
HIV-infected and HIV-uninfected patients. Although a subset of patients experienced severe 
symptoms, including vision loss, most patients recovered visual function following 
treatment.
The epidemiology of ocular syphilis in North Carolina is similar to that reported in previous 
investigations. The predominance of ocular syphilis in men, particularly men aged >40 
years, is consistent with what has been reported recently in the United States [14], and 
elsewhere [6, 7]. The high proportion of cases in men and MSM is also consistent with the 
epidemiology of syphilis in the United States [1]. However, studies from the United 
Kingdom [6] and the Netherlands [7] found a lower proportion of ocular syphilis patients 
known to be HIV infected (31.7% and 35.9%, respectively) than our investigation.
The extent to which HIV infection influences the development or severity of ocular 
symptoms in ocular syphilis is unclear. This investigation found a higher prevalence of 
ocular syphilis among HIV-infected syphilis cases, compared to syphilis cases without HIV. 
However, in this investigation and another US-based investigation, only half of patients 
diagnosed with ocular syphilis were HIV infected [14]. In previous studies of ocular 
syphilis, HIV-infected patients were more likely to be diagnosed with posterior uveitis [4, 
19], and have findings in follow-up suggesting possible treatment failure [20, 21]. More 
recent studies, however, have not found a relationship between HIV status and anatomical 
location of uveitis, CSF abnormalities, bilateral eye disease, presenting or final visual acuity, 
or reactive CSF VDRL [6, 7, 14]. While the presence of HIV infection alone might not 
determine ocular involvement, the degree of immunosuppression from HIV could modify 
ocular symptoms. CDC's 8-jurisdiction evaluation found that patients with a CD4 count 
<500 cells/μL were more likely to have a reactive CSF VDRL and bilateral ocular disease 
[14]. Although not statistically significant, this investigation found that, among HIV-infected 
ocular syphilis patients, those with a low CD4 count were more likely to present without 
other more common syphilis symptoms, compared to patients with a higher CD4 count.
Treatment of ocular syphilis is important for visual function improvement. In a report from 
the preantibiotic era, 9%–12% of patients with syphilitic iritis developed blindness [22]. In a 
retrospective review, worse posttreatment visual acuity was noted with a treatment delay of 
>12 weeks after symptom onset, while improved posttreatment visual acuity was observed in 
those treated with IV antibiotics [7]. A recent report of 6 cases described 2 patients with 
blindness after delayed treatment for ocular syphilis [5]. In our investigation, lack of other 
syphilis manifestations was associated with delayed treatment. In addition, patients who 
were assessed by an eye doctor had almost a week's delay in initiation of treatment. While 
we did not find this to be associated with vision loss or residual visual defects, other studies 
have found clinical implications associated with treatment delays [5, 7]. Provider education, 
especially for eye doctors who might not be accustomed to screening for syphilis, could 
potentially shorten delays in treatment.
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We were unable to assess differences in outcome after treatment between patients who 
received IV penicillin and those who received IM penicillin only, because of small numbers 
and substantial differences between these populations; none of the patients who received 
only IM penicillin had a severe eye diagnosis or presented with vision loss.
Most patients reported health insurance at the time of diagnosis. Lack of health insurance 
coverage was associated with residual visual deficits. Although no difference was found in 
time to care or treatment by insurance status, it is possible that differences in healthcare 
access could have impacted outcomes. Furthermore, lack of health insurance could have 
resulted in a subset of persons with ocular syphilis remaining undiagnosed, and therefore not 
identified by our investigation.
This investigation had several limitations. First, awareness of ocular syphilis in North 
Carolina increased over the course of our investigation; DIS were encouraged to ask about 
ocular symptoms and utilize the “eye/conjunctiva” checkbox in 2015, potentially leading to 
an increase in case ascertainment in 2015, compared to 2014. If ocular symptoms were not 
uniformly elicited and recorded during routine syphilis investigations, our numbers could be 
an underestimate of the true ocular syphilis burden. This could also have led to 
misclassification of true ocular cases as nonocular syphilis cases, potentially biasing results 
of our comparisons. Additionally, patients presenting to a clinician with ocular symptoms 
who never received a syphilis diagnosis are missing from our analysis. With respect to 
patient interviews, follow-up time varied by patient and could have impacted symptom 
recall. Additionally, eyesight in follow-up interviews was based on self-reported visual 
function, not standardized examinations. Finally, we did not interview syphilis patients 
without ocular manifestations, limiting our ability to compare some characteristics (eg, 
healthcare access).
The increase in reports of ocular syphilis, in North Carolina and across the United States, 
may be due to increased recognition of ocular manifestations in the setting of increased 
syphilis cases, or a true increase in the proportion of syphilis cases with ocular disease. We 
could not assess trends over time, because systematically collected information on suspected 
ocular syphilis is not available before 2014 in North Carolina. Preliminary reports from 
North Carolina in 2016 show a stable or slight increase in the proportion of syphilis patients 
with ocular manifestations (data not shown). While this was one of the largest ocular 
syphilis investigations published to date, further investigation is needed to better understand 
the increase in reports of ocular syphilis, and to identify potential risk factors influencing 
development of ocular disease.
The number of ocular syphilis cases increased in North Carolina during 2014–2015, in the 
context of an increase in all syphilis diagnoses. Ocular manifestations of syphilis can have 
substantial impact on visual function, even causing vision loss. Patients with syphilis should 
be asked about symptoms of syphilis complications, including vision or neurologic changes. 
All patients diagnosed with syphilis who have ocular manifestations should immediately be 
treated for neurosyphilis with IV penicillin and referred for ophthalmologic examination. In 
addition, patients with inflammatory eye disease without a known cause should have an 
evaluation of syphilis, regardless of risk factors. Prompt identification of ocular syphilis, 
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urgent ophthalmologic evaluation, and appropriate treatment are critical for management of 
ocular syphilis.
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Figure 1. 
Ocular syphilis case identification and follow-up interview participation—North Carolina, 
2014–2015.
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Figure 2. 
Mean visual function score by activity and time period—North Carolina, 2014–2015. 
“Before” was defined as prior to having eye or vision problems related to syphilis; “During” 
was defined as when syphilis-related eye or vision symptoms were at their worst; “Today” 
was defined as the time of the follow-up interview.
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Table 1
Demographic and Clinical Characteristics of Patients Diagnosed With Ocular Syphilis—
North Carolina, 2014–2015 (n = 63)
Characteristics No. (%)
Male 59 (94)
Known MSMa 42 (71)
Race
 Black 29 (46)
 White 32 (51)
 Other 2 (3)
Stage of syphilis
 Primary or secondary 24 (38)
 Early latent 9 (14)
 Late latent or latent of unknown durationb 30 (48)
Syphilis symptoms
 Genital lesions 3 (5)
 Skin rash 32 (51)
 Alopecia 4 (6)
 Condyloma lata 2 (3)
Ocular symptoms only 25 (40)
HIV infected 35 (56)
CSF analysis performed 38 (60)
CSF VDRL reactivec 24 (63)
Treatment
 Aqueous penicillin G IVd 42 (67)
 Benzathine penicillin IM only 13 (21)
 Other treatment 5 (8)
 No/unknown treatment 3 (5)
Eye examination
 Consistent with ocular syphilis 49 (78)
 No eye examination documented 14 (22)
Diagnosise
 Scleritis/keratitis 1 (2)
 Anterior uveitis 13 (21)
 Posterior uveitis 8 (13)
 Panuveitis 17 (27)
 Retinitis 9 (14)
 Optic neuritis 5 (8)
 Retinal detachment 2 (3)
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Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IM, intramuscular; I V, intravenous; MSM, men who have sex with 
men; VDRL, Venereal Disease Research Laboratory test.
a
Percentage calculated of males.
b
Includes late latent, late with clinical manifestations, and latent of unknown duration.
c
Percentage calculated of those with CSF analysis performed.
d
Patient could have received benzathine penicillin IM in addition to aqueous penicillin G IV.
e
Patient can be included in >1 category.
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Table 2
Demographic and Other Characteristics Associated With Ocular Syphilis, North 
Carolina, 2014–2015
Characteristic Total Syphilis 
Casesa (N = 4232)
Ocular Syphilis 
Cases (n = 63)
Prevalence of 
Ocular Syphilis, %
Prevalence Ratio (95% 
CI)
Sex
 Female 677 4 0.6 Ref
 Male 3542 59 1.7 2.82 (1.03–7.73)
Race
 Black 2674 29 1.1 Ref
 White 1124 32 2.9 2.63 (1.60–4.32)
 Other 429 2 0.5 0.45 (.11–1.86)
Age, y
 <40 2889 25 0.9 Ref
 ≥40 1343 38 2.8 3.27 (1.98–5.39)
Year diagnosed
 2014 1799 21 1.2 Ref
 2015 2435 42 1.7 1.48 (.88–2.49)
Reported MSM (among men only)
 No reported MSM behavior 1170 22 1.9 Ref
 MSM 2372 37 1.6 0.83 (.49–1.40)
Previous history of syphilis
 No 3549 56 1.6 Ref
 Yes 683 7 1.0 0.65 (.30–1.42)
Stage of syphilis
 Primary/secondary 1757 24 1.4 Ref
 Early latent 1083 9 0.8 0.61 (.28–1.30)
 Late latent or latent of unknown 
durationb
1392 30 2.2 1.58 (.93–2.69)
HIV status
 HIV uninfected/unknown 2488 28 1.1 Ref
 HIV infected 1744 35 2.0 1.78 (1.09–2.92)
Bolded prevalence ratios are considered statistically significant, where the confidence intervals do not include 1.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men.
aNumbers may not add to 4232 due to missing values.
b
Includes late latent, late with clinical manifestations, and latent of unknown duration.
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